ClinicalTrials.gg

Program

sepofarsen

Also written as “QR-110”.

Its studies are mostly in Blindness · Optic Atrophy, Hereditary, Leber, led by 2 companies.

Furthest: phase 3, since Feb 3, 20255 company-led studies, 2 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratoires Thea31 open or runningphase 3since Feb 3, 2025May 1, 2017Nov 2027phase 3 · NCT06891443
ProQR Therapeutics21 open or runningphase 3since Feb 21, 2019Feb 21, 2019none ahead

Also a collaborator on its studies: sepul-bio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2017First study: phase 2 study in Optic Atrophy, Hereditary, LeberNew to Laboratoires TheaLaboratoires Thea · NCT03140969 · 11 enrolled · United States, Belgium
  2. Feb 21, 2019ProQR Therapeutics's first study: phase 3 study in Leber Congenital Amaurosis 10New to ProQR TherapeuticsProQR Therapeutics · NCT03913143 · 36 enrolled · United States, Belgium, Brazil and more
  3. Feb 21, 2019Phase 2 study in Leber Congenital Amaurosis 10Laboratoires Thea · NCT03913130 · 9 enrolled · United States, Belgium
  4. Apr 13, 2021Phase 3 study in Leber Congenital Amaurosis 10ProQR Therapeutics · NCT04855045 · 15 enrolled · Belgium, Brazil, Canada and more
  5. Feb 3, 2025Phase 3 study in Leber Congenital Amaurosis 10Laboratoires Thea · NCT06891443 · 32 planned · United States, Australia, Belgium and more

Ahead

  1. Nov 2027Primary completion: phase 3 study in Leber Congenital Amaurosis 10Laboratoires Thea · NCT06891443

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06891443Leber Congenital Amaurosis 10 · United States, Australia, Belgium and more3RecruitingLaboratoires TheaNov 202732
NCT04855045Leber Congenital Amaurosis 10 · Belgium, Brazil, Canada and more3UNKNOWNProQR TherapeuticsDec 202315
NCT03913143Leber Congenital Amaurosis 10 · United States, Belgium, Brazil and more3Active, not recruitingProQR TherapeuticsJan 31, 202236
NCT03913130Leber Congenital Amaurosis 10 · United States, Belgium2TerminatedLaboratoires TheaOct 3, 20229
NCT03140969Optic Atrophy, Hereditary, Leber · United States, Belgium2CompletedLaboratoires TheaOct 2, 201911

How it is read

Names in the registry

  • “sepofarsen”, 3 entries
  • “QR-110”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.